Trial · NCT01528345
Adverse events200
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 200
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | ANAEMIA | Blood and lymphatic system disorders | Fulvestrant + Dovitinib Active | 9 | 47 | |
| other | ANAEMIA | Blood and lymphatic system disorders | Fulvestrant + Dovitinib Placebo | 4 | 50 | |
| other | LEUKOPENIA | Blood and lymphatic system disorders | Fulvestrant + Dovitinib Active | 3 | 47 | |
| other | LEUKOPENIA | Blood and lymphatic system disorders | Fulvestrant + Dovitinib Placebo | 0 | 50 | |
| other | NEUTROPENIA | Blood and lymphatic system disorders | Fulvestrant + Dovitinib Active | 7 | 47 | |
| other | NEUTROPENIA | Blood and lymphatic system disorders | Fulvestrant + Dovitinib Placebo | 0 | 50 | |
| other | EAR PAIN | Ear and labyrinth disorders | Fulvestrant + Dovitinib Active | 5 | 47 | |
| other | EAR PAIN | Ear and labyrinth disorders | Fulvestrant + Dovitinib Placebo | 0 | 50 | |
| other | VERTIGO | Ear and labyrinth disorders | Fulvestrant + Dovitinib Active | 6 | 47 | |
| other | VERTIGO | Ear and labyrinth disorders | Fulvestrant + Dovitinib Placebo | 0 | 50 | |
| other | DRY EYE | Eye disorders | Fulvestrant + Dovitinib Active | 5 | 47 | |
| other | DRY EYE | Eye disorders | Fulvestrant + Dovitinib Placebo | 0 | 50 | |
| other | LACRIMATION INCREASED | Eye disorders | Fulvestrant + Dovitinib Active | 6 | 47 | |
| other | LACRIMATION INCREASED | Eye disorders | Fulvestrant + Dovitinib Placebo | 0 | 50 | |
| other | VISION BLURRED | Eye disorders | Fulvestrant + Dovitinib Active | 3 | 47 | |
| other | VISION BLURRED | Eye disorders | Fulvestrant + Dovitinib Placebo | 0 | 50 | |
| other | ABDOMINAL DISTENSION | Gastrointestinal disorders | Fulvestrant + Dovitinib Active | 4 | 47 | |
| other | ABDOMINAL DISTENSION | Gastrointestinal disorders | Fulvestrant + Dovitinib Placebo | 3 | 50 | |
| other | ABDOMINAL PAIN | Gastrointestinal disorders | Fulvestrant + Dovitinib Active | 8 | 47 | |
| other | ABDOMINAL PAIN | Gastrointestinal disorders | Fulvestrant + Dovitinib Placebo | 5 | 50 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01528345/events